Hemab Therapeutics Holdings
COAG
39.29
-0.57
-1.43%
Hemab Therapeutics Holdings
US · COAG
#3007 by market cap
Listed 2026
39.29
-0.57
-1.43%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Hemab Therapeutics Holdings
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded in 2020 and is headquartered in Cambridge, MA.
- Founded
- 2020
- CEO
- Mr. Benny Sorensen, M.D.,PhD
- Employees
- 72
- Headquarters
- Cambridge, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- hemab.com
Company profile
- Exchange
- US
- Symbol
- COAG
- Market-cap rank
- #3007
- Listing date
- 2026-05-01
- Market cap
- 1.84B
- Float cap
- 835.96M
- Shares out
- 46.73M
- Float shares
- 21.28M
Sectors & themes
Biotechnology
IPOs
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Hemab Therapeutics Holdings discussion 0 comments